Researchers Find Diminished Response by Killer T Cells in Elderly COVID-19 Patients
Highlights
- Elderly patients have higher risk of severe illness and death from COVID-19.
- A new analysis of blood from people with COVID-19 found that the immune system of patients older than 80 produce fewer of the T cells that help expel virus-infected cells from the body compared to patients younger than 80.
- The researchers also found that CD8+ T cells in older patients produced lower frequencies of the cytotoxic molecules that find and kill infected cells.
- This immune response may partially explain why older patients have more severe illness.
WASHINGTON, D.C. – September 21, 2020 – Although people of any age can become infected with SARS-CoV-2, the virus that causes COVID-19, elderly patients face a higher risk of severity and death than younger patients. New research comparing the immune response among age groups, published , an open-access journal of the º£½ÇÉçÇøapp, may help explain why. Older patients with the disease have lower frequencies of the immune cells needed to expel the virus from the body, the researchers found.
“Elderly people have more severe diseases compared to young people, and we found that the cytotoxic part of immune control is not as efficient to respond to the virus in older people,” said virologist Gennadiy Zelinskyy, Ph.D., at the University Hospital Essen, in Germany. Zelinskyy led the new study.
He and his colleagues analyzed blood samples from 30 people with mild cases of COVID-19 to observe how T cells, which are necessary for recognition and elimination of infected cells, respond during SARS-CoV-2 infection. Patient ages ranged from the mid-20s to the late 90s. In all patients, the investigators found that acute SARS-CoV-2 infections led to lower numbers of T cells in the blood of the patients, compared to healthy individuals.
This reduction has been one of many unwelcome surprises from COVID-19, said Zelinskyy. Most viruses, once inside the body, trigger an uptick in the immune system’s expansion of T cells. These include “killer” T cells, which play a critical role in eradicating virus-infected cells. They produce cytotoxic molecules that destroy infected cells in the body. But if a person’s immune system produces fewer of these T cells, said Zelinskyy, it will be less successful at fighting off a viral infection.
In the COVID-19 patient group studied by Zelinskyy and his colleagues, the researchers similarly found that the number of CD8+ T cells producing cytotoxic molecules in response to virus diminished with increased age, and that reduction was significantly higher, on average, in patients over 80. Moreover, the “killer” T cells from patients aged 80-96 produced cytotoxic molecules at a lower frequency than similar cells from younger patients.
The SARS-CoV-2 virus attaches to cells in the nose or mouth. From there, it may spread to the lungs and move on to other organs, triggering a life-threatening infection. “Cytotoxic T cells really fight for control during this acute phase of infection,” Zelinskyy said. If an elderly patient’s immune system produces fewer killer T cells, and these cells are inadequately armed, he said, they may be mounting an insufficient defense against SARS-CoV-2. The viral particles can continue to spread and, as a result, the infection worsens.
The new data suggest that cytotoxic T cells play a key role in control of early infections, but Zelinskyy cautioned that it’s too soon to know if that connection can be harnessed to design an effective immunotherapy that uses these cells. In previous studies on viral infections in mice, his group found that a checkpoint inhibitor—an immunotherapy that activates killer T cells and effectively releases the brakes on the immune system—improved virus control at first but had the potential to later cause damage to the lungs and other organs. Further studies are warranted, he said, to better understand the potential risks and benefits of interfering with T cells as a way to control SARS-CoV-2 and other viruses.
#
º£½ÇÉçÇøappis keeping the pulse on the SARS-CoV-2 pandemic with the COVID-19 Research Registry of top-ranked research articles curated by experts. In the eye of a pandemic, this curated database will ensure that scientists, journalists and the public have an efficient way to find the timeliest and most valuable SARS-CoV-2/COVID-19 research from the latest journal articles and preprints.
The º£½ÇÉçÇøapp is one of the largest professional societies dedicated to the life sciences and is composed of 30,000 scientists and health practitioners. ASM's mission is to promote and advance the microbial sciences.
º£½ÇÉçÇøappadvances the microbial sciences through conferences, publications, certifications, educational opportunities and advocacy efforts. It enhances laboratory capacity around the globe through training and resources. It provides a network for scientists in academia, industry and clinical settings. Additionally, º£½ÇÉçÇøapppromotes a deeper understanding of the microbial sciences to diverse audiences.
